cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.3535/v0k-esh-1jj
title: Typha latifolia L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0l-0an-kwe
title: Carex elongata L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0l-3pt-2qh
title: Elymus repens (L.) Gould

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0l-b5l-zmv
title: Carex mackenziei V.I.Krecz.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0l-c2r-y35
title: Noccaea Moench

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0l-p2l-dhk
title: Carex lepidocarpa var. lepidocarpa

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0l-qgq-z9d
title: Viscaria vulgaris Röhl.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0l-rlz-q12
title: Juncus stygius L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0l-xkq-qxn
title: Athyrium filix-femina (L.) Roth

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0l-zh7-qeb
title: Festuca ovina L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0m-z1x-qbq
title: Geum urbanum L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0n-1va-t8s
title: Ficaria verna Huds.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0n-5q8-9mr
title: Cerastium arvense L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0n-g56-e81
title: Carex flava L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0n-0lx-p0y
title: Corydalis nobilis (L.) Pers.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0n-3mt-ypc
title: Aira praecox L.

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/v0n-k7z-tp1
title: Alchemilla monticola Opiz

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.5281/zenodo.17150847
title: Denormalized occurrence table of the Paleobiology Database

description: Comprehensive denormalized occurrence table built with the API of the Paleobiology Database  (http://paleobiodb.org/). Archived for the Chronosphere project by Ádám T. Kocsis. 

Downloaded on 2025-09-18 with the API call:
https://paleobiodb.org/data1.2/occs/list.csv?datainfo&rowcount&interval=Ediacaran,Holocene&show=class,classext,genus,subgenus,coll,coords,loc,paleoloc,strat,stratext,lith,env,ref,crmod,timebins,timecompare,refattr,entname,attr,ident,img,plant,abund,ecospace,taphonomy,etbasis,pres,prot,lithext,geo,methods,resgroup,refattr,ent
Contents: 

pbdb_occs.rds: occurrence table in binary R data file.
pbdb_parquet.zip: occurrence table, zipped parquet file
pbdb_csv.zip: occurrence table, zipped csv file
metadata.txt: The metadata of the download.
DOI: 10.15468/dl.z5ks38
title: Occurrence Download

description: A dataset containing 3003 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "HasCoordinate is true",
 "Year is 1969"
 ]
}

 The dataset includes 3003 records from 24 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014103-250914085247600/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.17131979
title: Assessing the Contribution of EU's ecosystem mapping (MAES) -- Projects to filling IPBES knowledge gaps

description: The data from national MAES projects (Mapping and Assessment of Ecosystems and their Services) can help address knowledge gaps identified by IPBES and the IPCC. We identified and clustered 51 consolidated knowledge gaps based on the IPBES Europe and Central Asia Assessment Report and the Europe chapter of the IPCC Climate Change 2022 Report. Subsequently, we consulted experts from 14 European countries and French Guiana to identify sources of new knowledge that could help address these knowledge gaps.

Details on methods and results are in the RESPIN project Deliverable 2.3.

This database was prepared under the Horizon Europe RESPIN project (Task 2.3). RESPIN - REinforcing Science-Policy INterfaces for integrated biodiversity and climate knowledge and policies (https://respin-project.eu/), contract number is 101135490.
DOI: 10.5281/zenodo.17150452
title: Data sets for article: "Towards fatigue failure prediction via acoustic emission analysis"

description: •    "SDs_experiment1" and "SDs_experiment2" contain the SDs for each experiment across the relevant frequencies, where each row represents an event and each column corresponds to a frequency.•    "cycle_number_experiment1" and "cycle_number_experiment2" provide the cycle number for each event as a decimal number, where the integer part before the decimal point indicates the cycle number and the fractional part after the decimal point represents the relative time within the cycle.
DOI: 10.5281/zenodo.17150451
title: Data sets for article: "Towards fatigue failure prediction via acoustic emission analysis"

description: •    "SDs_experiment1" and "SDs_experiment2" contain the SDs for each experiment across the relevant frequencies, where each row represents an event and each column corresponds to a frequency.•    "cycle_number_experiment1" and "cycle_number_experiment2" provide the cycle number for each event as a decimal number, where the integer part before the decimal point indicates the cycle number and the fractional part after the decimal point represents the relative time within the cycle.
DOI: 10.15468/dl.ebfwy4
title: Occurrence Download

description: A dataset containing 453 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Zemeros flegyas",
 "Country is China",
 "HasCoordinate is true"
 ]
}

 The dataset includes 453 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014105-250914085247600/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.sxnmgr
title: Occurrence Download

description: A dataset containing 63 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Pimelodella transitoria)",
 "BasisOfRecord is one of (Specimen, Literature Occurrence, Human Observation, Observation)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 1991",
 "Year is less than or equal to 2025"
 ]
}

 The dataset includes 63 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014104-250914085247600/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30155989
title: Supplementary Material for: VETC+ unresectable HCCs benefit of anti-angiogenic therapy

description: Introduction. Two distinct molecular groups of HCC have been recently associated with a better response to atezolizumab-bevacizumab (A/B). One of these, “angiogenesis-driven”, is related to HCC vascularization. VETC (vessel that encapsulate tumor clusters) is a morphological form of angiogenesis associated with worse prognosis in resected and transplanted HCC. 
Aim of this study is to explore if VETC can be used, at morphological level, to potentially surrogate the angiogenesis-driven molecular subgroup to identify HCC patients who mightbenefit of anti-angiogenic treatments.
Methods. The significance of VETC was first explored in a retrospective, single institution series of 75 patients with unresectable HCC (study cohort) and later validated in an external, retrospective series of 82 patients (validation cohort). The VETC phenotype was identified in the liver biopsy obtained just before the onset of systemic treatment.
Results. Patients with VETC+ HCC experienced a significant survival benefit from anti-angiogenic drugs, as tyrosine kinase inhibitors and/or bevacizumab (TKI/BEVA), across the study, validation, and overall cohorts. In the whole series of 157 patients, those with VETC+ HCC (n=70, 45%) treated with TKI/BEVA had a significantly longer OS as compared to those receiving Immune Checkpoint Inhibitors (ICIs) [19.8 months vs 8.8 months; HR 0.34; 95% CI 0.20-0.59; P=0.0001]. The significant treatment-by-biomarker interaction test (P=0.002) demonstrated that treatment effect varies by VETC status. Case with higher extent of VETC+, or with VETC+ detected before the onset of 1st line treatment showed even longer survival.
Conclusion. VETC+ predicts a significantly longer OS in patients with unresectable HCC treated with TKI/BEVA and can be used as surrogate marker on liver biopsy of angiogenesis-driven molecular class.
DOI: 10.6084/m9.figshare.30155989.v1
title: Supplementary Material for: VETC+ unresectable HCCs benefit of anti-angiogenic therapy

description: Introduction. Two distinct molecular groups of HCC have been recently associated with a better response to atezolizumab-bevacizumab (A/B). One of these, “angiogenesis-driven”, is related to HCC vascularization. VETC (vessel that encapsulate tumor clusters) is a morphological form of angiogenesis associated with worse prognosis in resected and transplanted HCC. 
Aim of this study is to explore if VETC can be used, at morphological level, to potentially surrogate the angiogenesis-driven molecular subgroup to identify HCC patients who mightbenefit of anti-angiogenic treatments.
Methods. The significance of VETC was first explored in a retrospective, single institution series of 75 patients with unresectable HCC (study cohort) and later validated in an external, retrospective series of 82 patients (validation cohort). The VETC phenotype was identified in the liver biopsy obtained just before the onset of systemic treatment.
Results. Patients with VETC+ HCC experienced a significant survival benefit from anti-angiogenic drugs, as tyrosine kinase inhibitors and/or bevacizumab (TKI/BEVA), across the study, validation, and overall cohorts. In the whole series of 157 patients, those with VETC+ HCC (n=70, 45%) treated with TKI/BEVA had a significantly longer OS as compared to those receiving Immune Checkpoint Inhibitors (ICIs) [19.8 months vs 8.8 months; HR 0.34; 95% CI 0.20-0.59; P=0.0001]. The significant treatment-by-biomarker interaction test (P=0.002) demonstrated that treatment effect varies by VETC status. Case with higher extent of VETC+, or with VETC+ detected before the onset of 1st line treatment showed even longer survival.
Conclusion. VETC+ predicts a significantly longer OS in patients with unresectable HCC treated with TKI/BEVA and can be used as surrogate marker on liver biopsy of angiogenesis-driven molecular class.
DOI: 10.6084/m9.figshare.30155992
title: Supplementary Material for: Comparison of Annual Dynamic Abbreviated MRI and Biannual Ultrasound for HCC Surveillance in a High-risk Group: Two Center Cohort Study

description: Introduction: Biannual ultrasound (US) is recommended for HCC surveillance, although its sensitivity for early-stage HCC is low. This study aims to compare the performance of annual dynamic abbreviated MRI (D-AMRI) and biannual US for HCC detection.
Methods: This prospective, two-center cohort study enrolled participants eligible for HCC surveillance according to Korean guidelines between November 2018 and December 2021. Participants underwent four rounds of surveillance at 6-month intervals: both D-AMRI and US at the first and third rounds and only US at the second and fourth rounds. The diagnostic yield (DY) and false referral rate (FRR) were compared between the two modalities. The scan time of D-AMRI was measured using a stopwatch.
Results: Of the 257 enrolled participants, 213 participants completed the protocol and were included in the analysis. Primary liver cancers were found in 32 participants, including 31 HCCs (22 very early-stage, eight early-stage, and one advanced-stage) and one intrahepatic cholangiocarcinoma. The DY of annual D-AMRI was higher than biannual US for all (6.4% [26/405] vs. 2.2% [9/405]), early-stage (6.2% [25/405] vs. 2.0% [8/405]), and very early-stage HCCs (4.7% [19/405] vs. 1.2% [5/405]) (P &lt;0.001 for all). No significant difference in the FRR was observed for all (2.5% [10/405] for both), early-stage (2.7% [11/405] for both) (P &gt;0.999 for both), and very early-stage HCCs (4.2% [17/405] vs. 3.5% [14/405], P = 0.564). The median scan time of D-AMRI was 13 min. 
Conclusion: Annual D-AMRI showed a higher DY than biannual US for detecting HCCs, without increasing the FRR.
DOI: 10.6084/m9.figshare.30155992.v1
title: Supplementary Material for: Comparison of Annual Dynamic Abbreviated MRI and Biannual Ultrasound for HCC Surveillance in a High-risk Group: Two Center Cohort Study

description: Introduction: Biannual ultrasound (US) is recommended for HCC surveillance, although its sensitivity for early-stage HCC is low. This study aims to compare the performance of annual dynamic abbreviated MRI (D-AMRI) and biannual US for HCC detection.
Methods: This prospective, two-center cohort study enrolled participants eligible for HCC surveillance according to Korean guidelines between November 2018 and December 2021. Participants underwent four rounds of surveillance at 6-month intervals: both D-AMRI and US at the first and third rounds and only US at the second and fourth rounds. The diagnostic yield (DY) and false referral rate (FRR) were compared between the two modalities. The scan time of D-AMRI was measured using a stopwatch.
Results: Of the 257 enrolled participants, 213 participants completed the protocol and were included in the analysis. Primary liver cancers were found in 32 participants, including 31 HCCs (22 very early-stage, eight early-stage, and one advanced-stage) and one intrahepatic cholangiocarcinoma. The DY of annual D-AMRI was higher than biannual US for all (6.4% [26/405] vs. 2.2% [9/405]), early-stage (6.2% [25/405] vs. 2.0% [8/405]), and very early-stage HCCs (4.7% [19/405] vs. 1.2% [5/405]) (P &lt;0.001 for all). No significant difference in the FRR was observed for all (2.5% [10/405] for both), early-stage (2.7% [11/405] for both) (P &gt;0.999 for both), and very early-stage HCCs (4.2% [17/405] vs. 3.5% [14/405], P = 0.564). The median scan time of D-AMRI was 13 min. 
Conclusion: Annual D-AMRI showed a higher DY than biannual US for detecting HCCs, without increasing the FRR.
DOI: 10.6084/m9.figshare.30155995
title: Supplementary Material for: Increasing Temporal Trends in the Frequency of Methamphetamine-Associated Intracerebral Hemorrhage in the Philippines

description: Introduction: Methamphetamine is an established risk factor for intracerebral hemorrhage (ICH). Despite growing concerns over its abuse, particularly in the Philippines, region-specific data on its neurological consequences remain lacking. This study aimed to investigate the temporal trends in the frequency of methamphetamine-associated ICH (Meth-ICH) in the Philippines.
Methods: Consecutive patients presenting with ICH at the Philippine National Specialty Center for Brain and Spine Care between 2018 and 2024 were retrospectively included. Meth-ICH cases were identified through positive urine toxicology tests at the time of admission. Frequency counts of total ICH and Meth-ICH cases were used to calculate the proportion of Meth-ICH cases for each year. Temporal trends were assessed using the two-sided Cochrane-Armitage test for trend, and by analyzing absolute and relative changes in proportions.
Results: Of the 1,652 ICH patients included, 116 (7.02%) tested positive for methamphetamine. The proportion of Meth-ICH cases increased 11.82-fold over the seven-year study period, rising from 1.49% (4/268, 95% confidence interval [CI]: 1.15% to 1.83%) in 2018 to 17.58% (74/421, 95% CI: 14.04% to 21.12%) in 2024. Between 2018 and 2021, no significant changes were observed in the number and proportion of Meth-ICH cases. A non-significant upward trend was noted between 2021 and 2022, with a relative change in proportion of 67.30% (95% CI: -86.57% to 231.17%; p = .635). A significant increase in the proportion of Meth-ICH cases was seen between 2022 and 2024, with relative changes in proportion of 310.70% (95% CI: 213.70% to 407.70%; p = .003) from 2022 to 2023, and 100.80% (95% CI: 5.89% to 207.69%; p = .001) from 2023 to 2024.
Conclusion: There was an increasing trend in the frequency of Meth-ICH cases in the Philippines from 2018 to 2024, with a significant and sustained surge beginning in 2022. Comprehensive evidence-based public health strategies are urgently needed, particularly in regions with high rates of methamphetamine use.
DOI: 10.6084/m9.figshare.30155995.v1
title: Supplementary Material for: Increasing Temporal Trends in the Frequency of Methamphetamine-Associated Intracerebral Hemorrhage in the Philippines

description: Introduction: Methamphetamine is an established risk factor for intracerebral hemorrhage (ICH). Despite growing concerns over its abuse, particularly in the Philippines, region-specific data on its neurological consequences remain lacking. This study aimed to investigate the temporal trends in the frequency of methamphetamine-associated ICH (Meth-ICH) in the Philippines.
Methods: Consecutive patients presenting with ICH at the Philippine National Specialty Center for Brain and Spine Care between 2018 and 2024 were retrospectively included. Meth-ICH cases were identified through positive urine toxicology tests at the time of admission. Frequency counts of total ICH and Meth-ICH cases were used to calculate the proportion of Meth-ICH cases for each year. Temporal trends were assessed using the two-sided Cochrane-Armitage test for trend, and by analyzing absolute and relative changes in proportions.
Results: Of the 1,652 ICH patients included, 116 (7.02%) tested positive for methamphetamine. The proportion of Meth-ICH cases increased 11.82-fold over the seven-year study period, rising from 1.49% (4/268, 95% confidence interval [CI]: 1.15% to 1.83%) in 2018 to 17.58% (74/421, 95% CI: 14.04% to 21.12%) in 2024. Between 2018 and 2021, no significant changes were observed in the number and proportion of Meth-ICH cases. A non-significant upward trend was noted between 2021 and 2022, with a relative change in proportion of 67.30% (95% CI: -86.57% to 231.17%; p = .635). A significant increase in the proportion of Meth-ICH cases was seen between 2022 and 2024, with relative changes in proportion of 310.70% (95% CI: 213.70% to 407.70%; p = .003) from 2022 to 2023, and 100.80% (95% CI: 5.89% to 207.69%; p = .001) from 2023 to 2024.
Conclusion: There was an increasing trend in the frequency of Meth-ICH cases in the Philippines from 2018 to 2024, with a significant and sustained surge beginning in 2022. Comprehensive evidence-based public health strategies are urgently needed, particularly in regions with high rates of methamphetamine use.
DOI: 10.6084/m9.figshare.30155998
title: Supplementary Material for: An ethical framework for addressing the differential impact of systemic racism and inequities on type 1 and type 2 diabetes mellitus in youth in the United States

description: Background: Inequities in the clinical care and health outcomes of youth and young adults (YYA) with type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2D) are well-established. Systemic and institutional racism and barriers, as well as implicit biases underlie these inequities in the United States.
Summary: This article offers a broad overview and analysis of disparities in clinical care and outcomes among youth and young adults (YYA) with type 1 and type 2 diabetes, framed within an ethical context. We argue that achieving ethical care requires centering assessments of patient and family needs within the realities of their lived experiences, as well as structural barriers and challenges. We examine the impact of structural racism and implicit bias on clinical care and explore how factors such as non-English language communication, literacy, numeracy, nutrition, school nursing services, access to diabetes technology and medications, and insurance disparities influence diabetes management and outcomes. The article concludes with a call to action and concrete recommendations to address and reduce these inequities.
Key Messages: Clinicians can play a pivotal role in reducing diabetes-related health care disparities by adopting an ethical approach that centers upon lived experiences of YYA with diabetes thereby identifying opportunities for more equitable care.
DOI: 10.6084/m9.figshare.30155998.v1
title: Supplementary Material for: An ethical framework for addressing the differential impact of systemic racism and inequities on type 1 and type 2 diabetes mellitus in youth in the United States

description: Background: Inequities in the clinical care and health outcomes of youth and young adults (YYA) with type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2D) are well-established. Systemic and institutional racism and barriers, as well as implicit biases underlie these inequities in the United States.
Summary: This article offers a broad overview and analysis of disparities in clinical care and outcomes among youth and young adults (YYA) with type 1 and type 2 diabetes, framed within an ethical context. We argue that achieving ethical care requires centering assessments of patient and family needs within the realities of their lived experiences, as well as structural barriers and challenges. We examine the impact of structural racism and implicit bias on clinical care and explore how factors such as non-English language communication, literacy, numeracy, nutrition, school nursing services, access to diabetes technology and medications, and insurance disparities influence diabetes management and outcomes. The article concludes with a call to action and concrete recommendations to address and reduce these inequities.
Key Messages: Clinicians can play a pivotal role in reducing diabetes-related health care disparities by adopting an ethical approach that centers upon lived experiences of YYA with diabetes thereby identifying opportunities for more equitable care.
DOI: 10.15468/dl.wxc5y3
title: Occurrence Download

description: A dataset containing 17035 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Vachellia macracantha",
 "HasCoordinate is true"
 ]
}

 The dataset includes 17035 records from 145 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014106-250914085247600/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.7k8hkm
title: Occurrence Download

description: A dataset containing 2518 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-21.9301 -40.14751,64.51626 -40.14751,64.51626 38.01529,-21.9301 38.01529,-21.9301 -40.14751))",
 "TaxonKey is Xylopia aethiopica"
 ]
}

 The dataset includes 2518 records from 105 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0014107-250914085247600/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.